Christian Clark's questions to Xeris Biopharma Holdings Inc (XERS) leadership • Q2 2025
Question
Christian Clark of Leerink Partners questioned if Xeris plans to generate additional clinical data to strengthen RECORLEV's value proposition, particularly concerning its effect on secondary comorbidities like stubborn diabetes.
Answer
CEO John Shannon affirmed that while there are long-term plans to generate more data, RECORLEV's existing clinical dataset already demonstrates the resolution of comorbidities, such as diabetes, when the underlying elevated cortisol levels are treated. He stated the company will continue to generate more data around this.